|[August 26, 2014]
Vaxxas Selected as World Economic Forum Technology Pioneer 2015
CAMBRIDGE, Mass. & BRISBANE, Queensland --(Business Wire)--
a biotechnology company commercializing a novel vaccine delivery
platform, has been named a 2015 Technology
Pioneer by the World Economic Forum.
Vaxxas is one of 24 emerging technology companies from around the world
and across all industries recognized for their potential to transform
the future of business and society.
Vaxxas is developing the Nanopatch™, a novel vaccine delivery platform
designed to enable more efficient, effective, and safer vaccination than
needle and syringe. The Nanopatch™ achieves these benefits by directly
targeting delivery of vaccine components to the abundant immunological
cells immediately below the surface of the skin, resulting in robust
immune system activation at much lower doses than required by needle
injection. Vaccines delivered by the Nanopatch™ platform have the
potential to provide vastly improved immune protection at significantly
lower cost. Furthermore, when vaccines are dry-coated onto the
proprietary Nanopatch™, they have thermostable properties, which means
that the billions of dollars needed to maintain the cold-chain may
somday be reinvested toward more pressing priorities in global health
systems. Vaxxas is pursuing strategic plans to both license its
technology to global pharmaceutical companies as well as advance vaccine
candidates on its own.
"We are so pleased to receive this recognition from the World Economic
Forum," said David L. Hoey, President and CEO of Vaxxas. "It's really a
validation of our potential. Indeed, we see a significant number of
opportunities where our technology can have a dramatic positive impact
on improving global health, and we are actively seeking financial and
strategic partners with the resources and expertise to support our
global commercial plans."
Each year the World Economic Forum chooses a select number of Technology
Pioneers from hundreds of applicants. Candidate companies are nominated
by Members, constituents and collaborators of the World Economic Forum,
and by the public. A selection committee, comprised of top technology
and innovation experts, academics and venture capitalists, reviews all
applications before making its recommendation to the World Economic
About the World Economic Forum
The World Economic Forum is an independent international organization
committed to improving the state of the world by engaging business,
political, academic and other leaders of society to shape global,
regional and industry agendas.
Incorporated as a not-for-profit foundation in 1971 and headquartered in
Geneva, Switzerland, the Forum is tied to no political, partisan or
national interests (www.weforum.org).
is a privately-held biotechnology company focused on enhancing the
performance of existing and next-generation vaccines with its
proprietary Nanopatch™ technology platform. Vaxxas' Nanopatch contains
an ultra-high density array of very short projections - invisible to the
naked eye - that are dry-coated with vaccine. Application of the
Nanopatch to the skin is pain free and rapidly delivers the vaccine to
the abundant immune cell population immediately below the skin surface.
In a wide range of preclinical studies Nanopatch delivery of vaccine
achieves equivalent protective immunity as the needle and syringe - but
with as little as 1/100th of the dose. It has also been shown
that Vaxxas' proprietary dry-coating technology can eliminate the need
for vaccine refrigeration during storage and transportation - removing
the resource burden of maintaining the "cold chain." Leveraging both the
potent immunogenic response and thermostability, Vaxxas is applying its
technology to improve the performance of vaccines, with initial
applications targeting infectious disease and oncology. The company has
its first announced pharmaceutical company collaboration with Merck.
[ Back To TMCnet.com's Homepage ]